IMS: 2014 Top Ten hospital medicine products overall market performance statistics, first quarter 2

Three heavy signal early afternoon
IMS: 2014 Top Ten hospital medicine products overall market performance statistics, first quarter 2014 sales of Chinese hospital pharmaceutical market (hospital pharmacy purchase amount) to 144.04 billion yuan (Source: IMS Health report on Chinese medicine hospital statistics IMS 100 beds), compared to last year sales growth of 12.9%. The growth rate of the previous quarter's growth rate has declined about 2%. Based on 12 months of MAT (rolling annual data: Specifies the time the sum of the data nodes backdated 12 months, here refers to the second quarter of 2013 to the first quarter of 2014 sales) point of view, 2014 MAT growth dalmacija news rate of 13.8% in the first quarter, essentially flat with the previous quarter. Mainly due to continued growth slowdown is still limited due to the impact of anti-government orders, especially for local enterprise products, and since 2011, after the five drug prices, the total control of the intensity of large hospitals in major cities increased, prescription drugs conservative, especially in the use of antibiotics and medical solutions, these factors are no doubt the market slowdown. Multinational and domestic enterprises market performance in the first quarter 2014 growth of local enterprises was 12.5% from the previous quarter fell nearly 3 percent, but compared with 12.1% in the first quarter of 2013, essentially flat. Multinational impressive gains, was 14.2% for the first time in recent years is the growth of more than local companies. Scroll annual data, domestic enterprises are still ahead. Throughout the first quarter of 2014 corporate sales performance, with sales of 3.66 billion yuan of Pfizer and 18.2% growth rate continued to maintain its leading position in the Chinese hospital pharmaceutical market. AstraZeneca to 2.99 billion yuan in sales ranked second, with sales of 2.462 billion yuan Qilu Pharmaceutical ranked third, dalmacija news this result continues the best ranking Chinese enterprises. From the rolling annual data, the most rapidly growing Novartis Pharmaceuticals (25.7%), followed by Qilu Pharmaceutical (19.8%), AstraZeneca is ranked third (18.7%). Chinese Hospital in channel sales to cover Shandong, Henan, Jiangsu, Zhejiang, Guangdong and Sichuan provinces 40% six multinationals in Guangdong and Zhejiang outstanding, are able to achieve more than 30% market share. Level in four cities, the growth rate of the city's lowest level, while market growth in key areas of primary and secondary cities is the multinationals, three, four cities are mostly contributed by local businesses. Drug sales of all therapeutic areas and downs of other products (mainly proprietary) has become dalmacija news China's largest therapeutic area hospital market, with sales in the first quarter of 2014, 27.92 billion yuan currency people, the growth rate reached 12.9%. Systemic anti-infective product growth has become more stabilized, reaching 10.6 percent, and continued growth in the fourth quarter of 2013. From a product point of view, the first quarter of 2014 there were seven local products and three multinational companies located in the top ten products product list. The top three products in the local enterprise products accounted for two seats, respectively, ranked first Xueshuantong, quarterly sales to 86.3 million yuan, ranked top hospital dalmacija news medicine; Jie Shen to 84.1 million yuan in the quarter, sales rose to second dalmacija news place. Ranked third in the Sanofi Plavix verification code: Please enter the verification code after clicking listening verification code